Is Booking Holdings Stock Undervalued?
There is a lot of humdrum in the market about…
Sell
22
STRO Quote, Financials, Valuation and Earnings
Last price:
$1.94
Seasonality move
:
-13.05%
Day range:
$1.80 - $1.90
52-week range:
$1.70 - $6.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.82x
P/B ratio:
1.36x
Volume:
770.5K
Avg. volume:
1.3M
1-year change:
-57.11%
Market cap:
$151.7M
Revenue:
$153.7M
EPS (TTM):
-$1.61
Analysts' Opinion
-
Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.50, Sutro Biopharma has an estimated upside of 525% from its current price of $1.84.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.84.
Fair Value
-
According to the consensus of 8 analysts, Sutro Biopharma has 525% upside to fair value with a price target of $11.50 per share.
STRO vs. S&P 500
-
Over the past 5 trading days, Sutro Biopharma has overperformed the S&P 500 by 1.01% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sutro Biopharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sutro Biopharma revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Sutro Biopharma reported revenues of $8.5M.
Earnings Growth
-
Sutro Biopharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Sutro Biopharma reported earnings per share of -$0.59.
Enterprise value:
-236.5M
EV / Invested capital:
--
Price / LTM sales:
0.82x
EV / EBIT:
--
EV / Revenue:
-1.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
2.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-27.59%
Net Income Margin (TTM):
-77.01%
Return On Equity:
-99.41%
Return On Invested Capital:
-97.66%
Operating Margin:
-797.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $69.8M | $48.6M | $161M | $16.9M | $8.5M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$114.8M | -$181.7M | -$130M | -$44M | -$67.9M | |
| EBITDA | -$110.1M | -$149.1M | -$66M | -$37M | -$39.1M | |
| Diluted EPS | -$2.59 | -$2.91 | -$1.61 | -$0.81 | -$0.59 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $292.3M | $250.7M | $346.6M | $381.3M | $405.8M | |
| Total Assets | $307.2M | $371.5M | $400.7M | $431.7M | $451.8M | |
| Current Liabilities | $29.9M | $35.5M | $58.3M | $73.6M | $131.3M | |
| Total Liabilities | $63.1M | $87.9M | $171M | $319.4M | $340.6M | |
| Total Equity | $244.1M | $283.6M | $229.7M | $112.3M | $111.2M | |
| Total Debt | $24.4M | $25M | $19.3M | $7.1M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $5.8M | -$149.6M | -$105.7M | -$33.5M | -$64.5M | |
| Cash From Investing | $23.6M | -$18.3M | $107.5M | -$114M | $147.3M | |
| Cash From Financing | $36.6M | $152.9M | $91M | -$5.7M | $1M | |
| Free Cash Flow | -$1.2M | -$155.8M | -$109.2M | -$33.8M | -$65.3M | |
STRO
Sector
Market Cap
$151.7M
$47.7M
Price % of 52-Week High
30.02%
46.05%
Dividend Yield
0%
0%
Shareholder Yield
-33.14%
-0.74%
1-Year Price Total Return
-57.11%
-33.33%
Beta (5-Year)
1.153
0.760
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.88
200-day SMA
Sell
Level
$3.66
Bollinger Bands (100)
Sell
Level
2.59 - 4.27
Chaikin Money Flow
Sell
Level
-32.2M
20-day SMA
Sell
Level
$2.21
Relative Strength Index (RSI14)
Sell
Level
28.89
ADX Line
Sell
Level
22.57
Williams %R
Buy
Level
-82.0513
50-day SMA
Sell
Level
$2.89
MACD (12, 26)
Sell
Level
-0.31
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
21M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.4671)
Sell
CA Score
(Annual)
Level (-1.3716)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.2023)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Stock Forecast FAQ
In the current month, STRO has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The STRO average analyst price target in the past 3 months is $11.50.
-
Where Will Sutro Biopharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sutro Biopharma share price will rise to $11.50 per share over the next 12 months.
-
What Do Analysts Say About Sutro Biopharma?
Analysts are divided on their view about Sutro Biopharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sutro Biopharma is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Sutro Biopharma's Price Target?
The price target for Sutro Biopharma over the next 1-year time period is forecast to be $11.50 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is STRO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sutro Biopharma is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of STRO?
You can purchase shares of Sutro Biopharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sutro Biopharma shares.
-
What Is The Sutro Biopharma Share Price Today?
Sutro Biopharma was last trading at $1.94 per share. This represents the most recent stock quote for Sutro Biopharma. Yesterday, Sutro Biopharma closed at $1.84 per share.
-
How To Buy Sutro Biopharma Stock Online?
In order to purchase Sutro Biopharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Broadcom vs American Express: Which Is Best?
Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…
Why Is Adobe Stock Dropping?
Why is Adobe stock dropping? A combination of underwhelming fiscal…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 41x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
25
DRUG alert for Jan 2
Bright Minds Biosciences [DRUG] is up 13.55% over the past day.
Buy
56
QMCO alert for Jan 2
Quantum [QMCO] is up 0.83% over the past day.
Buy
78
BMA alert for Jan 2
Banco Macro SA [BMA] is up 12.94% over the past day.
